Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

Jason Gotlib, Caroline Berubé, Joseph D. Growney, Ching Cheng Chen, Tracy I. George, Christopher Williams, Tomohiro Kajiguchi, Jia Ruan, Stan L. Lilleberg, Jeffrey A. Durocher, Jack H. Lichy, Yanfeng Wang, Pamela S. Cohen, Daniel A. Arber, Michael Heinrich, Len Neckers, Stephen J. Galli, D. Gary Gilliland, Steven E. Coutré

Research output: Contribution to journalArticle

201 Citations (Scopus)

Abstract

The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease.

Original languageEnglish (US)
Pages (from-to)2865-2870
Number of pages6
JournalBlood
Volume106
Issue number8
DOIs
StatePublished - Oct 2005
Externally publishedYes

Fingerprint

4'-N-benzoylstaurosporine
Mast-Cell Leukemia
Protein-Tyrosine Kinases
Systemic Mastocytosis
Myeloproliferative Disorders
Mutation
Myelodysplastic Syndromes
Inhibitory Concentration 50
Phosphorylation
Receptor Protein-Tyrosine Kinases
Cell growth
Clonal Evolution
Liver
Histamine
Therapeutic Uses
Blood
Mutation Rate
Acute Myeloid Leukemia
Mast Cells
Blood Cells

ASJC Scopus subject areas

  • Hematology

Cite this

Gotlib, J., Berubé, C., Growney, J. D., Chen, C. C., George, T. I., Williams, C., ... Coutré, S. E. (2005). Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood, 106(8), 2865-2870. https://doi.org/10.1182/blood-2005-04-1568

Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. / Gotlib, Jason; Berubé, Caroline; Growney, Joseph D.; Chen, Ching Cheng; George, Tracy I.; Williams, Christopher; Kajiguchi, Tomohiro; Ruan, Jia; Lilleberg, Stan L.; Durocher, Jeffrey A.; Lichy, Jack H.; Wang, Yanfeng; Cohen, Pamela S.; Arber, Daniel A.; Heinrich, Michael; Neckers, Len; Galli, Stephen J.; Gilliland, D. Gary; Coutré, Steven E.

In: Blood, Vol. 106, No. 8, 10.2005, p. 2865-2870.

Research output: Contribution to journalArticle

Gotlib, J, Berubé, C, Growney, JD, Chen, CC, George, TI, Williams, C, Kajiguchi, T, Ruan, J, Lilleberg, SL, Durocher, JA, Lichy, JH, Wang, Y, Cohen, PS, Arber, DA, Heinrich, M, Neckers, L, Galli, SJ, Gilliland, DG & Coutré, SE 2005, 'Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation', Blood, vol. 106, no. 8, pp. 2865-2870. https://doi.org/10.1182/blood-2005-04-1568
Gotlib, Jason ; Berubé, Caroline ; Growney, Joseph D. ; Chen, Ching Cheng ; George, Tracy I. ; Williams, Christopher ; Kajiguchi, Tomohiro ; Ruan, Jia ; Lilleberg, Stan L. ; Durocher, Jeffrey A. ; Lichy, Jack H. ; Wang, Yanfeng ; Cohen, Pamela S. ; Arber, Daniel A. ; Heinrich, Michael ; Neckers, Len ; Galli, Stephen J. ; Gilliland, D. Gary ; Coutré, Steven E. / Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. In: Blood. 2005 ; Vol. 106, No. 8. pp. 2865-2870.
@article{02d1968115f244bd859372c986b24f84,
title = "Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation",
abstract = "The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50{\%} inhibitory concentration (IC50) of 30 nM to 40 nM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease.",
author = "Jason Gotlib and Caroline Berub{\'e} and Growney, {Joseph D.} and Chen, {Ching Cheng} and George, {Tracy I.} and Christopher Williams and Tomohiro Kajiguchi and Jia Ruan and Lilleberg, {Stan L.} and Durocher, {Jeffrey A.} and Lichy, {Jack H.} and Yanfeng Wang and Cohen, {Pamela S.} and Arber, {Daniel A.} and Michael Heinrich and Len Neckers and Galli, {Stephen J.} and Gilliland, {D. Gary} and Coutr{\'e}, {Steven E.}",
year = "2005",
month = "10",
doi = "10.1182/blood-2005-04-1568",
language = "English (US)",
volume = "106",
pages = "2865--2870",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation

AU - Gotlib, Jason

AU - Berubé, Caroline

AU - Growney, Joseph D.

AU - Chen, Ching Cheng

AU - George, Tracy I.

AU - Williams, Christopher

AU - Kajiguchi, Tomohiro

AU - Ruan, Jia

AU - Lilleberg, Stan L.

AU - Durocher, Jeffrey A.

AU - Lichy, Jack H.

AU - Wang, Yanfeng

AU - Cohen, Pamela S.

AU - Arber, Daniel A.

AU - Heinrich, Michael

AU - Neckers, Len

AU - Galli, Stephen J.

AU - Gilliland, D. Gary

AU - Coutré, Steven E.

PY - 2005/10

Y1 - 2005/10

N2 - The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease.

AB - The majority of patients with systemic mast cell disease express the imatinib-resistant Asp816Val (D816V) mutation in the KIT receptor tyrosine kinase. Limited treatment options exist for aggressive systemic mastocytosis (ASM) and mast cell leukemia (MCL). We evaluated whether PKC412, a small-molecule inhibitor of KIT with a different chemical structure from imatinib, may have therapeutic use in advanced SM with the D816V KIT mutation. We treated a patient with MCL (with an associated myelodysplastic syndrome (MDS)/myeloproliferative disorder [MPD]) based on in vitro studies demonstrating that PKC412 could inhibit D816V KIT-transformed Ba/F3 cell growth with a 50% inhibitory concentration (IC50) of 30 nM to 40 nM. The patient exhibited a partial response with significant resolution of liver function abnormalities. In addition, PKC412 treatment resulted in a significant decline in the percentage of peripheral blood mast cells and serum histamine level and was associated with a decrease in KIT phosphorylation and D816V KIT mutation frequency. The patient died after 3 months of therapy due to progression of her MDS/MPD to acute myeloid leukemia (AML). This case indicates that KIT tyrosine kinase inhibition is a feasible approach in SM, but single-agent clinical efficacy may be limited by clonal evolution in the advanced leukemic phase of this disease.

UR - http://www.scopus.com/inward/record.url?scp=27144506215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27144506215&partnerID=8YFLogxK

U2 - 10.1182/blood-2005-04-1568

DO - 10.1182/blood-2005-04-1568

M3 - Article

VL - 106

SP - 2865

EP - 2870

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -